(vianews) - the market ended the session with dbv technologies (dbv.pa) rising 10.17% to €1.97 on wednesday while cac 40 rose 0.04% to €7,571.82.
dbv technologies's last close was €1.79, 58.37% below its 52-week high of €4.30.
about dbv technologies
dbv technologies s.a., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. its lead product candidate is viaskin peanut, an immunotherapy product, which has completed phase iii clinical trial for the treatment of peanut allergies. the company is also developing viaskin milk that is in phase i/ii clinical trial for the treatment of immunoglobulin e (ige) mediated cow's milk protein allergy (cmpa) and eosinophilic esophagitis. its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for crohn's disease, celiac disease, and type i diabetes. the company has a collaboration with nestlé health science to develop mag1c, a ready-to-use atopy patch test for the diagnosis of non-ige mediated cmpa in infants and toddlers. dbv technologies s.a. was incorporated in 2002 and is headquartered in montrouge, france.
earnings per share
as for profitability, dbv technologies has a trailing twelve months eps of €-1.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -56.61%.
volatility
dbv technologies's last week, last month's, and last quarter's current intraday variation average was a negative 1.91%, a positive 0.89%, and a positive 2.46%.
dbv technologies's highest amplitude of average volatility was 1.91% (last week), 2.79% (last month), and 2.46% (last quarter).
moving average
dbv technologies's value is higher than its 50-day moving average of €1.81 and way under its 200-day moving average of €2.77.more news about dbv technologies (dbv.pa).